Paper40958736
Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers.
Ozcan AI and 4 others. J Surg Oncol, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers. Papers, record 40958736. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40958736
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers.
- PubMed
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Peritoneal Neoplasms | Major topic |
| Immunotherapy | Major topic |
| Humans |
Source PubMed
References288
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17067392 | Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. | Mol Cancer | 2006 | https://conductscience.org/library/papers/17067392 | PubMed |
| 2 | 30187278 | Natural Killer Cell IFNγ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery. | Ann Surg Oncol | 2018 | https://conductscience.org/library/papers/30187278 | PubMed |
| 3 | 33081383 | Antibody-Drug Conjugates for Cancer Therapy. | Molecules | 2020 | https://conductscience.org/library/papers/33081383 | PubMed |
| 4 | 35327456 | Assessing the Future of Solid Tumor Immunotherapy. | Biomedicines | 2022 | https://conductscience.org/library/papers/35327456 | PubMed |
| 5 | 20090516 | MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain. | Appl Immunohistochem Mol Morphol | 2010 | https://conductscience.org/library/papers/20090516 | PubMed |
| 6 | 29329202 | EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/29329202 | PubMed |
| 7 | 27663893 | Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. | Cancer Discov | 2016 | https://conductscience.org/library/papers/27663893 | PubMed |
| 8 | 33614478 | Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms. | Front Oncol | 2020 | https://conductscience.org/library/papers/33614478 | PubMed |
| 9 | 38067347 | Peritoneal Metastasis: A Dilemma and Challenge in the Treatment of Metastatic Colorectal Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38067347 | PubMed |
| 10 | 34682772 | Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials. | J Clin Med | 2021 | https://conductscience.org/library/papers/34682772 | PubMed |
| 11 | 32698317 | Monoclonal Antibodies in Cancer Therapy. | Antibodies (Basel) | 2020 | https://conductscience.org/library/papers/32698317 | PubMed |
| 12 | 38086815 | Therapeutic cancer vaccines: advancements, challenges, and prospects. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/38086815 | PubMed |
| 13 | 37386139 | Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37386139 | PubMed |
| 14 | 33178203 | Localized Interleukin-12 for Cancer Immunotherapy. | Front Immunol | 2020 | https://conductscience.org/library/papers/33178203 | PubMed |
| 15 | 25762242 | Surgical stress response after colorectal resection: a comparison of robotic, laparoscopic, and open surgery. | Tech Coloproctol | 2015 | https://conductscience.org/library/papers/25762242 | PubMed |
| 16 | 24337648 | Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. | Ann Surg Oncol | 2014 | https://conductscience.org/library/papers/24337648 | PubMed |
| 17 | 36960052 | Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. | Front Immunol | 2023 | https://conductscience.org/library/papers/36960052 | PubMed |
| 18 | 38261129 | Reconnaissance for Intraperitoneal Immunotherapy. | Ann Surg Oncol | 2024 | https://conductscience.org/library/papers/38261129 | PubMed |
| 19 | 30962163 | Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. | Mol Ther | 2019 | https://conductscience.org/library/papers/30962163 | PubMed |
| 20 | 35326701 | Mesothelin: An Immunotherapeutic Target beyond Solid Tumors. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35326701 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 40958736 | Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers. | J Surg Oncol | 2025 | https://conductscience.org/library/papers/40958736 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40958736
GET https://conductscience.org/api/papers/v1/40958736/references?page=2